YOU STOPPED AT: "QUESTION #3: What if your PSA rises?...

WHAT IF YOUR PSA RISES? - SALVAGE THERAPY OPTIONS WITH YOUR REVISED NOMOGRAM

Let me complete this critical section about biochemical recurrence management.

---

QUESTION #3: WHAT IF YOUR PSA RISES?

Your Salvage Therapy Options

SCENARIO: PSA rises above undetectable (>0.2 ng/mL)

DEFINITION: Biochemical recurrence (BCR)
├─ PSA rises above your nadir (lowest point)
├─ Your nadir: 0.009 ng/mL (essentially undetectable)
├─ BCR threshold: Usually PSA >0.2 ng/mL on 2 consecutive tests
├─ Timeframe: Can occur months to years after surgery
└─ Frequency: Occurs in 20-23% of men with your nomogram result

IMPORTANT CONTEXT:
├─ BCR doesn't mean cancer has spread
├─ BCR means cancer cells may be present somewhere
├─ Could be: Local recurrence in prostate bed
├─ Could be: Micrometastases (tiny cancer deposits)
├─ Could be: Residual disease from focal positive margin
├─ Time to act: You have time to evaluate options
└─ Your advantage: Early detection through PSA surveillance

---

SALVAGE THERAPY OPTIONS IF PSA RISES

According to NCCN Guidelines for Prostate Cancer

IF PSA RISES - YOUR TREATMENT OPTIONS:

STEP 1: CONFIRM BIOCHEMICAL RECURRENCE
├─ Repeat PSA test to confirm rise
├─ Obtain 2 consecutive rising PSA values
├─ Rule out PSA bounce (temporary rise after surgery)
├─ Assess PSA doubling time (how fast it's rising)
├─ Assess PSA velocity (rate of change)
└─ Timeline: Usually takes 2-4 weeks to confirm

STEP 2: STAGING EVALUATION
├─ Determine if recurrence is local or distant
├─ Imaging options based on PSA level:
│
│  If PSA 0.2-1.0 ng/mL:
│  ├─ PSMA-PET scan (most sensitive)
│  ├─ Conventional imaging (CT/bone scan) less sensitive
│  └─ May not detect micrometastases
│
│  If PSA 1.0-2.0 ng/mL:
│  ├─ PSMA-PET scan (recommended)
│  ├─ Conventional imaging (CT/bone scan)
│  └─ Better detection of metastases
│
│  If PSA >2.0 ng/mL:
│  ├─ PSMA-PET scan (highly recommended)
│  ├─ Conventional imaging (CT/bone scan)
│  ├─ Bone scan
│  └─ Higher likelihood of detecting disease
│
└─ Goal: Determine if cancer is local or has spread

STEP 3: TREATMENT OPTIONS BASED ON FINDINGS

OPTION A: LOCAL RECURRENCE (Cancer in prostate bed only)
┌─────────────────────────────────────────────────────────────┐
│ SALVAGE RADIATION THERAPY (SRT)                             │
│                                                             │
│ What it is:                                                 │
│ • External beam radiation to prostate bed                   │
│ • Targets area where prostate was removed                   │
│ • Dose: 64-70 Gy over 8-9 weeks                             │
│                                                             │
│ When it's recommended:                                      │
│ • PSA recurrence with no distant metastases                 │
│ • PSA <2.0 ng/mL (better outcomes)                          │
│ • Life expectancy >10 years                                 │
│ • Good performance status                                   │
│                                                             │
│ Effectiveness (per NCCN):                                   │
│ • 40-50% achieve PSA control at 5 years                     │
│ • Better outcomes if PSA <1.0 at time of SRT                │
│ • Earlier treatment (lower PSA) = better results            │
│                                                             │
│ Side effects:                                               │
│ • Urinary symptoms (frequency, urgency, dysuria)            │
│ • Bowel symptoms (diarrhea, rectal bleeding)                │
│ • Erectile dysfunction (if not already present)             │
│ • Most side effects mild to moderate                        │
│                                                             │
│ Combination approach:                                       │
│ • SRT + hormone therapy often used together                 │
│ • Hormone therapy (ADT) added for 2-3 years                 │
│ • Improves outcomes compared to SRT alone                   │
│ • Especially if PSA >1.0 or high-risk features              │
│                                                             │
│ YOUR SPECIFIC SITUATION:                                    │
│ • Your focal apical margin makes SRT relevant               │
│ • If PSA rises, SRT would target prostate bed               │
│ • Your pT2 stage is favorable for SRT outcomes              │
│ • Your Gleason 7 may warrant SRT + ADT combination          │
│ • Early detection (through surveillance) = better outcomes  │
└─────────────────────────────────────────────────────────────┘

OPTION B: DISTANT METASTASES (Cancer has spread)
┌─────────────────────────────────────────────────────────────┐
│ SYSTEMIC THERAPY (Hormone therapy ± other treatments)       │
│                                                             │
│ What it is:                                                 │
│ • Androgen deprivation therapy (ADT)                        │
│ • Targets cancer throughout the body                        │
│ • May include additional agents                             │
│                                                             │
│ When it's recommended:                                      │
│ • Metastatic recurrence (cancer has spread)                 │
│ • PSA rising with imaging evidence of spread                │
│ • Life expectancy >5 years                                  │
│                                                             │
│ Treatment options:                                          │
│ • ADT alone (LHRH agonist or antagonist)                    │
│ • ADT + next-generation hormone therapy                     │
│   ├─ Abiraterone (Zytiga)                                   │
│   ├─ Enzalutamide (Xtandi)                                  │
│   ├─ Apalutamide (ARN-509)                                  │
│   └─ Darolutamide (ODM-201)                                 │
│ • ADT + chemotherapy (docetaxel)                            │
│ • Other options based on biomarkers                         │
│                                                             │
│ Effectiveness:                                              │
│ • ADT alone: Median progression-free survival 12-18 months  │
│ • ADT + next-gen hormone therapy: 18-24+ months             │
│ • Combination approaches: Better outcomes                   │
│                                                             │
│ Side effects:                                               │
│ • Hot flashes, fatigue, sexual dysfunction                  │
│ • Bone loss, metabolic changes                              │
│ • Cardiovascular effects (monitor needed)                   │
│ • Varies by specific agent used                             │
│                                                             │
│ YOUR SPECIFIC SITUATION:                                    │
│ • If metastases detected: Systemic therapy indicated        │
│ • Your Gleason 7 + PSA recurrence = intermediate-risk       │
│ • Treatment choice depends on specific metastases           │
│ • Biomarker testing may guide therapy selection             │
│ • Multiple options available - not one-size-fits-all        │
└─────────────────────────────────────────────────────────────┘

OPTION C: OLIGOMETASTATIC DISEASE (Few metastases)
┌─────────────────────────────────────